These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 28899429)

  • 1. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
    Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
    Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.
    Pyun JM; Park YH; Kim HR; Suh J; Kang MJ; Kim BJ; Youn YC; Jang JW; Kim S;
    Alzheimers Res Ther; 2017 Dec; 9(1):99. PubMed ID: 29246250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
    JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A biomarker study in long-lasting amnestic mild cognitive impairment.
    Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
    Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia.
    van der Veere PJ; Hoogland J; Visser LNC; Van Harten AC; Rhodius-Meester HF; Sikkes SAM; Venkatraghavan V; Barkhof F; Teunissen CE; van de Giessen E; ; Berkhof J; Van Der Flier WM
    Neurology; 2024 Aug; 103(3):e209605. PubMed ID: 38986053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
    Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
    J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
    Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
    Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 'Comprehensive Visual Rating Scale' for predicting progression to dementia in patients with mild cognitive impairment.
    Jang JW; Park JH; Kim S; Park YH; Pyun JM; Lim JS; Kim Y; Youn YC; Kim S;
    PLoS One; 2018; 13(8):e0201852. PubMed ID: 30125290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment.
    Moon B; Kim S; Park YH; Lim JS; Youn YC; Kim S; Jang JW;
    J Alzheimers Dis; 2017; 58(4):1255-1264. PubMed ID: 28550264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia.
    Eckerström C; Olsson E; Bjerke M; Malmgren H; Edman A; Wallin A; Nordlund A
    J Alzheimers Dis; 2013; 36(3):421-31. PubMed ID: 23635408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
    van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
    Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.